For generations, the sound of a dental drill has marked childhood's encounter with tooth decay — a condition affecting nearly half of all American children. Now, researchers from the University of Michigan and partner institutions have completed a landmark trial showing that a liquid called silver diamine fluoride, applied in seconds every six months, can stop cavities in more than half of treated baby teeth without pain, drilling, or significant cost. The study, published in JAMA Pediatrics, offers the large-scale clinical evidence needed to pursue formal FDA approval, and with it, the possib
Scientists Find Drill-Free Cavity Treatment That Works in Seconds
Tooth decay affects nearly half of US children, causing pain, infection, difficulty eating, and missed school days; this treatment could reduce suffering and healthcare burden.
A treatment that works in seconds, painless, no drilling required.
Mark
So this is a real alternative to drilling, not just marketing?
Mimi
The Phase III trial tested it in over 800 children under six. When applied every six months, it stopped cavities in more than half of the baby teeth treated. That's the data the FDA needs to consider approval.
Luke
But it's already been used off-label for years. What's new here?
Mimi
The rigorous evidence. Dentists have been using it informally, but this is the first large-scale U.S. trial that gives regulators the kind of data they require for formal approval as a cavity treatment.
Mark
Why does that matter if it's already working?
Mimi
Because formal approval opens doors—insurance coverage, wider adoption in public health programs, use in medical clinics, not just dental offices. Right now it's technically off-label.
Luke
And the cost difference is real?
Mimi
The source doesn't give exact numbers, but it's described as inexpensive and takes seconds. Traditional drilling requires anesthesia, removal of tooth material, filling placement. The economics are obvious.
Mark
What about the kids who are scared of dentists?
Mimi
That's part of the public health argument. Nearly half of U.S. children get cavities. If you can treat them painlessly and quickly, more families might actually seek care.
Luke
Do we know if it works equally well across all types of cavities, or just early decay?
Mimi
The study focused on early childhood tooth decay. The source doesn't specify whether it works on advanced cavities.
Mark
When might people actually see this available?
Luke
That depends on FDA approval, which isn't guaranteed yet. The trial provides the evidence, but the regulatory process is separate.
Mimi
And even after approval, adoption takes time. Dentists need training, insurance needs to cover it, practices need to stock it.
O Pulso
- Tooth decay quietly burdens nearly half of all American children, bringing pain, infection, missed school days, and procedures that many young children find frightening or inaccessible.
- A Phase III trial of more than 800 children under six — years in the making and tested through a pandemic — has now produced the rigorous evidence the FDA requires to consider approving silver diamine fluoride as a formal cavity treatment.
- The treatment itself takes only seconds: a liquid brushed onto the tooth, no drilling, no anesthesia, no tears — a striking departure from the standard of care that has defined pediatric dentistry for decades.
- SDF already exists, already has FDA clearance for tooth sensitivity, and is already used off-label by many dentists — meaning the infrastructure for adoption is closer than it might appear.
- The clearest beneficiaries would be low-income families and children who avoid dental care out of fear or cost, populations for whom untreated decay compounds into larger health and educational consequences.
- Formal approval and widespread adoption remain open questions, but the clinical foundation has been laid, and the direction of travel is now visible.
For generations, the sound of a dental drill has marked childhood's encounter with tooth decay — a condition affecting nearly half of all American children. Now, researchers from the University of Michigan and partner institutions have completed a landmark trial showing that a liquid called silver diamine fluoride, applied in seconds every six months, can stop cavities in more than half of treated baby teeth without pain, drilling, or significant cost. The study, published in JAMA Pediatrics, offers the large-scale clinical evidence needed to pursue formal FDA approval, and with it, the possibility that one of childhood's most common sources of suffering might be addressed with something as simple as a painted drop of liquid.
A liquid that can be painted onto a child's tooth in seconds, requiring no drilling and causing no pain, has now cleared a major scientific threshold in the effort to transform how tooth decay is treated in young children. Silver diamine fluoride, or SDF, was the subject of a large clinical trial published in JAMA Pediatrics, led by researchers at the University of Michigan alongside partners at NYU and the University of Iowa. Beginning in 2018 and persisting through the disruptions of the COVID-19 pandemic, the study followed more than 800 children under age six and found that applying SDF every six months stopped cavities in more than half of treated baby teeth.
The treatment is not new to the world. Several countries have used SDF for years, and the FDA approved it in 2014 — though only for reducing tooth sensitivity. Many American dentists already apply it off-label to slow decay, but it has never received formal regulatory clearance for that purpose. This Phase III trial was designed specifically to generate the large-scale U.S. evidence the FDA typically requires before expanding a substance's approved uses.
The stakes are significant. Tooth decay is among the most common chronic conditions in American childhood, affecting nearly half of all children and producing consequences that ripple outward — pain, infection, difficulty eating, and school absences. For families who delay or avoid dental care because of cost or a child's fear of the drill, an inexpensive and painless alternative could meaningfully change outcomes. Lead investigator Margherita Fontana noted that SDF can arrest decay and relieve the infection and pain it causes, even in children as young as one.
Whether the FDA grants formal approval for cavity treatment, and how quickly dental and public health systems move to adopt SDF at scale, remains to be seen. But the clinical evidence now exists in a form that regulators can act on, and the possibility of a quieter, gentler chapter in pediatric dental care is no longer hypothetical.
Researchers have identified a treatment for tooth decay that works in seconds, requires no drilling, and costs far less than conventional cavity care. The substance is silver diamine fluoride, a liquid painted directly onto the tooth's surface. In a large clinical trial published in JAMA Pediatrics, scientists found that applying SDF every six months stopped cavities in more than half of baby teeth treated in children under age six. The study involved more than 800 children and was led by researchers from the University of Michigan in partnership with New York University College of Dentistry and the University of Iowa. The work began in 2018 and continued through the disruptions of the COVID-19 pandemic.
The procedure itself is straightforward and painless. A dentist applies the liquid directly to the affected tooth, and the treatment is complete within seconds. This stands in sharp contrast to traditional cavity management, which requires drilling away decayed material and placing a filling—a process that can be frightening and difficult for young children, particularly those under six. Margherita Fontana, the study's lead investigator and a professor of dentistry at the University of Michigan, emphasized that the treatment is both effective and safe, even for children as young as one year old.
Silver diamine fluoride is not new. It has been used in several countries for years and has established a solid record as a cavity-control agent. In the United States, the Food and Drug Administration approved it in 2014, but only for reducing tooth sensitivity. Although many dentists already use it off-label to slow or stop tooth decay, it has not yet received formal regulatory approval for that specific purpose. The Phase III trial provides the large-scale clinical evidence the FDA typically requires when considering new medical applications for existing treatments. If approved, SDF could expand significantly in use across American dental practice.
The public health stakes are substantial. Nearly half of all children in the United States experience cavities, making tooth decay one of the most common chronic childhood conditions. The consequences extend beyond discomfort: decay causes pain, infection, difficulty eating, missed school days, and expensive dental procedures. An inexpensive, non-invasive option like SDF could make treatment accessible to families who might otherwise delay or avoid care, particularly low-income households. Fontana noted that the treatment can arrest decay and stop both the infection and the pain it produces, potentially benefiting many people.
The path forward depends on regulatory action and clinical adoption. Fontana emphasized that rigorous evidence—both of efficacy and safety—is essential for broader implementation, particularly if the treatment is to be used in medical settings beyond traditional dental offices. The trial data now provides that evidence in a U.S. population. Whether SDF receives formal FDA approval for cavity treatment and how quickly dentists and public health systems adopt it remain open questions, but the clinical foundation for change has been laid.
Citações Notáveis
This is a very effective and safe treatment—even in children as young as 1.— Margherita Fontana, lead investigator, University of Michigan School of Dentistry
For almost anyone, this can arrest the decay and stop the infection and the pain it causes. This could benefit many people.— Margherita Fontana
Quer a matéria completa?
Leia o original em The Economic Times ↗
Health & Medicine